Evidence map›Paper›PMID 31478285›Full record

ArticleAddiction (Abingdon, England)2020

Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis.

Olga Morozova, Forrest W Crawford, Ted Cohen, A David Paltiel, Frederick L Altice

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  3. Economic Evaluation in Opioid Modeling: Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Olga MorozovaDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0001-7606-8413
Forrest W CrawfordDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0002-0046-0547
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0002-8091-7198
A David PaltielYale School of Management, New Haven, CT, USA.ORCID 0000-0002-4861-3290
Frederick L AlticeDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0002-7860-693X

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Novel approaches to the design and evaluation of combination HIV preventionR01MH105203 · NIMH · YALE UNIVERSITY · PI PALTIEL, A. DAVID · 2014 to 2018
$3.3M
Network-based epidemiology for hidden and hard-to-reach populationsDP2HD091799 · NICHD · YALE UNIVERSITY · PI CRAWFORD, FORREST WRENN · 2016 to 2016
$2.5M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Optimizing Medication-Assisted Therapy for Opioid Dependence in Ukraine: HIV Impact Modeling and Cost-Effectiveness EvaluationR36DA042643 · NIDA · YALE UNIVERSITY · PI MOROZOVA, OLGA · 2016 to 2017
$98k
NCATS NIH HHS UL1 TR001863NICHD NIH HHS DP2 HD091799NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA015612NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA043125NIDA NIH HHS R36 DA042643NIDA NIH HHS R37 DA015612NIMH NIH HHS R01 MH105203
6 · The paper itself

Abstract

BACKGROUND AND

aimsAlthough opioid agonist treatment (OAT) for opioid use disorder (OUD) is cost-effective in settings where the HIV epidemic is concentrated among people who inject drugs, OAT coverage in Ukraine remains far below internationally recommended targets. Scale-up is limited by both OAT availability and demand. This study aimed to evaluate the cost-effectiveness of a range of plausible OAT scale-up strategies in Ukraine incorporating the potential impact of treatment spillover and the real-world demand for addiction treatment. DESIGN, SETTING AND

participantsTen-year horizon (2016-25) modeling study of opioid addiction epidemic and treatment that accommodated potential peer effects in opioid use initiation and supply-induced treatment demand in three Ukrainian cities: Kyiv, Mykolaiv and Lviv, comprising a simulated population of people at risk of and with OUD. MEASUREMENTS: Incremental cost per quality-adjusted life-year gained in the simulated population.

findingsAn estimated 12.2-, 2.4- and 13.4-fold OAT capacity increase over 2016 baseline capacity in Kyiv, Mykolaiv and Lviv, respectively, would be cost-effective at a willingness-to-pay of one per-capita gross domestic product (GDP) per quality-adjusted life-year gained. This result is robust to parametric and structural uncertainty. Even under the most ambitious capacity increase, OAT coverage (i.e. the proportion of people with OUD receiving OAT) over a 10-year modeling horizon would be 20, 11 and 17% in Kyiv, Mykolaiv and Lviv, respectively, owing to limited demand.

conclusionsIt is estimated that a substantial increase in opioid agonist treatment (OAT) capacity in three Ukrainian cities would be cost-effective for a wide range of willingness-to-pay thresholds. Even a very ambitious capacity increase, however, is unlikely to reach internationally recommended coverage levels. Further increases in coverage may be limited by demand and would require addressing existing structural barriers to OAT access.

Indexed as

Cost-Benefit AnalysisOpiate Substitution TreatmentAnalgesics, OpioidForecastingHealth Services Needs and DemandHIV InfectionsHumansModels, TheoreticalOpioid-Related DisordersUkraineAnalgesics, OpioidBuprenorphineEastern Europeeconomic evaluationinjection initiationmethadoneopioid epidemicpeople who inject drugs (PWID)treatment as preventiontreatment demandtreatment waiting-list

Identifiers

PMID31478285
PMCPMC7015766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.